Osteoporosis
Conditions
Interventions
Osteoporosis group:Basic treatment and anti-osteoporosis sequential treatment
Osteopenia group:Regular screening and basic treatment
Normal bone metabolism group:Regular screening
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects at risk of bone metabolism whose IOF one minute test result is "Yes"; 2. Definitely diagnose patients with osteopenia or osteoporosis; 3. Subjects who can keep regular visits (1-2 times per year), age>18 years (inclusive); 4. Sign the informed consent voluntarily; 5. Patients who can cooperate with the Holonomic Empower Management model of Bone and Metabolic Health.
Exclusion criteria
Exclusion criteria: 1. Patients with major organ failure or other serious diseases with unstable situation, including but not limited to patients with myocardial infarction, severe mental disorder, severe infection or disseminated intravascular coagulation within 12 months before enrollment; 2. Patients with active or inactive malignant tumors with life expectancy less than 1 year; 3. Patients who have communication barriers and cannot fully understand or cooperate; 4. Patients who cannot accept remote management based on applet or APP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bone mineral density;Cumulative fracture events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Annual BMD performance;Implementation of drug therapy within the anti osteoporosis treatment plan;Risk assessment and sequential execution degree in stage planning;Annual changes in BMD from baseline in patient treated with Oral diphosphate;Annual changes in Bone turnover index from baseline in patient treated with Oral diphosphate;Cumulative fracture events in patient treated with Oral diphosphate;Annual changes in BMD from baseline in patient treated with Intravenous diphosphate;Annual changes in Bone turnover index from baseline in patient treated with Intravenous diphosphate;Cumulative fracture events in patient treated with Intravenous diphosphate;Annual changes in BMD from baseline in patient treated with RANKL inhibitor;Annual changes in Bone turnover index from baseline in patient treated with RANKL inhibitor;Cumulative fracture events in patient treated with RANKL inhibitor;Annual changes in BMD from baseline in patient treated with Other anti osteoporosis drugs;Annual changes in Bone turnover index from baseline in patient treated with Other anti osteoporosis drugs;Cumulative fracture events in patient treated with Other anti osteoporosis drugs;Annual changes in BMD from baseline in Osteopenia patient treated with basic drugs;Annual changes in Bone turnover index from baseline in Osteopenia patient treated with basic drugs;Cumulative fracture events in Osteopenia patient treated with basic drugs;Cumulative incidence of major osteoporotic fractures (wrist, vertebral body, hip) among different subgroups;Cumulative fall incidence among different subgroups;Cumulative fracture/fall related hospitalization rates among different subgroups;Cumulative mortality among different subgroups;Direct costs of disease treatment for osteoporosis patients;Direct costs of bone metabolism related adverse events in patients with osteoporosis;Long term health economic benefits of managing osteoporosis patients calculated by health economics model; | — |
Countries
China
Contacts
Public ContactLi Ang
Peking University First Hospital
Outcome results
None listed